Free Trial

Healthcare and Medical Stocks List

This page shows information about the 50 largest healthcare and medical sector stocks including Eli Lilly and Company, Johnson & Johnson, AbbVie and UnitedHealth Group. Learn more about health care stocks.

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$696.08 -15.60 (-2.19%)
Closing price 03:59 PM Eastern
Extended Trading
$695.64 -0.44 (-0.06%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • The current stock price is around $710, which may present a buying opportunity for investors looking to enter at a lower price point compared to its 1-year high.
  • Recent earnings reports show strong performance, with revenue up significantly compared to the previous year, indicating robust business growth.
  • Analysts have a generally positive outlook, with a majority rating the stock as a "Buy" or "Strong Buy," suggesting confidence in the company's future performance.

Cons of Eli Lilly and Company

  • Recent analyst downgrades have occurred, with some firms reducing their price targets, which may indicate concerns about future growth potential.
  • The stock has experienced volatility, with significant price fluctuations over the past year, which could pose risks for investors seeking stability.
  • The company's high price-to-earnings (P/E) ratio suggests that the stock may be overvalued compared to its earnings, which could lead to a price correction.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$673.57 billion
P/E Ratio
45.50
Consensus Rating
Moderate Buy
Consensus Price Target
$950.17 (+36.5% Upside)
Volume
2.89 million shares
Average Volume
6.99 million shares
Today's Range
$694.23
$713.50
50-Day Range
$625.15
$811.73
52-Week Range
$623.78
$972.48
Dividend Yield
0.84%
Johnson & Johnson stock logo

2. Johnson & Johnson NYSE:JNJ

$178.53 -0.76 (-0.42%)
Closing price 03:59 PM Eastern
Extended Trading
$178.38 -0.15 (-0.08%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • The current stock price is around $178.72, which reflects a stable position in the market and potential for growth.
  • Johnson & Johnson reported a strong quarterly earnings performance, with earnings per share (EPS) of $2.77, exceeding analysts' expectations, indicating robust financial health.
  • The company has a solid revenue stream, with a reported revenue of $23.74 billion for the latest quarter, showcasing a year-over-year growth of 5.8%.

Cons of Johnson & Johnson

  • The stock has experienced fluctuations, with a 52-week low of $140.68, indicating potential volatility that could concern risk-averse investors.
  • Analysts have mixed ratings on the stock, with some downgrading their outlook, which may signal uncertainty about future performance.
  • The company's payout ratio is currently at 55.61%, which, while manageable, indicates that a significant portion of earnings is being distributed as dividends, potentially limiting reinvestment in growth opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$431.79 billion
P/E Ratio
19.09
Consensus Rating
Moderate Buy
Consensus Price Target
$176.29 (-1.3% Downside)
Volume
6.23 million shares
Average Volume
8.66 million shares
Today's Range
$178.29
$180.26
50-Day Range
$149.81
$179.10
52-Week Range
$140.68
$181.16
Dividend Yield
2.90%
AbbVie stock logo

3. AbbVie NYSE:ABBV

$207.58 -3.02 (-1.43%)
Closing price 03:59 PM Eastern
Extended Trading
$207.78 +0.19 (+0.09%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • The current stock price is around $210, reflecting a strong market presence and investor interest.
  • AbbVie has shown a year-over-year revenue increase, indicating growth potential and resilience in its business model.
  • Institutional investors hold a significant portion of AbbVie’s stock, suggesting confidence in the company's future performance.

Cons of AbbVie

  • The stock has a high price-to-earnings (P/E) ratio of 100.14, which may indicate that it is overvalued compared to its earnings.
  • AbbVie has a relatively high debt-to-equity ratio of 44.14, suggesting that the company relies significantly on debt financing, which can be risky.
  • Recent insider selling activity may raise concerns about the confidence of executives in the company's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$372.04 billion
P/E Ratio
98.85
Consensus Rating
Moderate Buy
Consensus Price Target
$214.95 (+3.6% Upside)
Volume
2.80 million shares
Average Volume
5.18 million shares
Today's Range
$207.05
$211.30
50-Day Range
$181.89
$210.28
52-Week Range
$163.81
$218.66
Dividend Yield
3.11%
UnitedHealth Group stock logo

4. UnitedHealth Group NYSE:UNH

$305.26 -2.16 (-0.70%)
Closing price 03:59 PM Eastern
Extended Trading
$304.01 -1.25 (-0.41%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. More about UnitedHealth Group

Pros of UnitedHealth Group

  • The company reported a significant year-over-year revenue increase of approximately 12.9%, indicating strong growth potential.
  • UnitedHealth Group has a robust return on equity of 23.32%, suggesting effective management and profitability in generating returns for shareholders.
  • The current stock price is around $365, which reflects a moderate buy consensus from analysts, indicating potential for appreciation.

Cons of UnitedHealth Group

  • The company missed earnings per share estimates by $0.37, which may raise concerns about its ability to meet market expectations.
  • Recent analyst downgrades have lowered price targets significantly, with some analysts reducing their target from $490 to $270, indicating potential bearish sentiment.
  • Insider selling, including a notable transaction by the CEO, may signal a lack of confidence in the stock's short-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$278.42 billion
P/E Ratio
13.23
Consensus Rating
Moderate Buy
Consensus Price Target
$365.38 (+19.7% Upside)
Volume
8.87 million shares
Average Volume
23.44 million shares
Today's Range
$302.73
$308.87
50-Day Range
$237.40
$325.83
52-Week Range
$234.60
$630.73
Dividend Yield
2.88%
Novartis stock logo

5. Novartis NYSE:NVS

$125.12 -1.86 (-1.46%)
Closing price 03:59 PM Eastern
Extended Trading
$125.04 -0.08 (-0.06%)
As of 07:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • Novartis AG recently reported strong earnings, with an EPS of $2.42, surpassing expectations, indicating robust financial health and effective management.
  • The company has shown significant revenue growth, with a quarterly revenue increase of over 12% compared to the same period last year, suggesting a strong demand for its healthcare products.
  • With a market capitalization of approximately $268.66 billion, Novartis AG is a major player in the pharmaceutical industry, providing stability and potential for long-term growth.

Cons of Novartis

  • Despite recent earnings success, the stock has experienced fluctuations in trading volume, which may indicate volatility and uncertainty in investor sentiment.
  • Novartis AG has a relatively high price-to-earnings (P/E) ratio of 18.51, which could suggest that the stock is overvalued compared to its earnings potential.
  • The company has a debt-to-equity ratio of 0.53, which, while manageable, indicates that it relies on debt financing, potentially increasing financial risk.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$268.24 billion
P/E Ratio
18.21
Consensus Rating
Hold
Consensus Price Target
$123.50 (-1.3% Downside)
Volume
705,698 shares
Average Volume
1.50 million shares
Today's Range
$124.99
$126.95
50-Day Range
$113.55
$127.18
52-Week Range
$96.06
$128.03
Dividend Yield
2.04%
Novo Nordisk A/S stock logo

6. Novo Nordisk A/S NYSE:NVO

$56.35 -0.63 (-1.11%)
Closing price 03:59 PM Eastern
Extended Trading
$56.33 -0.02 (-0.04%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • The current stock price is around $56.89, which may present a buying opportunity for investors looking for growth in the healthcare sector.
  • Recent earnings reports indicate strong performance, with earnings per share surpassing analysts' expectations, suggesting robust financial health.
  • The company has a high return on equity, indicating effective management and profitability, which can be attractive to investors seeking reliable returns.

Cons of Novo Nordisk A/S

  • The stock has experienced volatility, with a 52-week high of $139.74, indicating potential risks associated with price fluctuations.
  • Despite strong earnings, the revenue figures have not met consensus estimates, which could raise concerns about future growth prospects.
  • The company has a relatively low current ratio, suggesting potential liquidity issues that could affect its ability to meet short-term obligations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$254.42 billion
P/E Ratio
15.48
Consensus Rating
Hold
Consensus Price Target
$81.00 (+43.7% Upside)
Volume
16.13 million shares
Average Volume
29.65 million shares
Today's Range
$56.25
$58.34
50-Day Range
$45.31
$77.02
52-Week Range
$45.05
$139.74
Dividend Yield
1.44%
AstraZeneca stock logo

7. AstraZeneca NASDAQ:AZN

$79.66 -1.31 (-1.62%)
Closing price 04:00 PM Eastern
Extended Trading
$79.74 +0.08 (+0.10%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. More about AstraZeneca

Pros of AstraZeneca

  • The current stock price is around $80, reflecting a stable market position and potential for growth.
  • AstraZeneca has received positive ratings from analysts, with a consensus rating of "Moderate Buy" and a price target indicating potential upside.
  • Institutional investors hold a significant portion of the stock, indicating confidence in AstraZeneca's long-term prospects.

Cons of AstraZeneca

  • Despite recent positive movements, the stock has experienced fluctuations, which may indicate volatility in the market.
  • Some institutional investors have reduced their holdings, which could signal concerns about the company's future performance.
  • The pharmaceutical industry is highly competitive, and AstraZeneca faces challenges from other companies in developing new treatments.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$251.12 billion
P/E Ratio
29.95
Consensus Rating
Moderate Buy
Consensus Price Target
$86.00 (+8.0% Upside)
Volume
3.38 million shares
Average Volume
5.32 million shares
Today's Range
$79.49
$81.52
50-Day Range
$68.72
$80.97
52-Week Range
$61.24
$87.68
Dividend Yield
1.25%
Abbott Laboratories stock logo

8. Abbott Laboratories NYSE:ABT

$132.02 -0.57 (-0.43%)
Closing price 03:59 PM Eastern
Extended Trading
$132.01 -0.01 (-0.01%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • The current stock price is around $134, which is near its 12-month high, indicating strong market performance and investor confidence.
  • Abbott Laboratories reported a significant revenue increase of 7.4% year-over-year, showcasing its growth potential and ability to expand its market share.
  • The company has a solid net margin of over 32%, reflecting efficient operations and profitability, which can lead to higher returns for investors.

Cons of Abbott Laboratories

  • The price-to-earnings (P/E) ratio of 16.44 may suggest that the stock is overvalued compared to its earnings, which could deter value-focused investors.
  • Despite a low debt-to-equity ratio of 0.25, indicating financial stability, any increase in debt could impact the company's financial health and investor confidence.
  • The PEG ratio of 2.47 suggests that the stock may be priced high relative to its growth rate, which could limit future price appreciation.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$230.77 billion
P/E Ratio
16.54
Consensus Rating
Moderate Buy
Consensus Price Target
$144.47 (+9.4% Upside)
Volume
4.71 million shares
Average Volume
5.69 million shares
Today's Range
$131.49
$132.96
50-Day Range
$120.76
$138.13
52-Week Range
$110.86
$141.23
Dividend Yield
1.78%
Merck & Co., Inc. stock logo

9. Merck & Co., Inc. NYSE:MRK

$85.43 -1.94 (-2.22%)
Closing price 03:59 PM Eastern
Extended Trading
$85.38 -0.05 (-0.06%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • The current stock price is around $87, which reflects a stable valuation in the market.
  • Merck has a strong market capitalization of approximately $217.76 billion, indicating a robust position in the pharmaceutical industry.
  • The company reported earnings per share of $2.13, surpassing analysts' expectations, which suggests strong financial performance.

Cons of Merck & Co., Inc.

  • Recent analyst reports have shown a reduction in target prices, indicating potential concerns about future growth.
  • Merck's price-to-earnings ratio of 13.43 may suggest that the stock is fairly valued, limiting upside potential.
  • The company has faced revenue estimates that were not met, which could signal challenges in maintaining growth momentum.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$218.23 billion
P/E Ratio
13.16
Consensus Rating
Hold
Consensus Price Target
$107.44 (+25.8% Upside)
Volume
9.25 million shares
Average Volume
12.24 million shares
Today's Range
$84.95
$87.39
50-Day Range
$78.17
$87.18
52-Week Range
$73.31
$120.30
Dividend Yield
3.71%
Thermo Fisher Scientific stock logo

10. Thermo Fisher Scientific NYSE:TMO

$490.73 -9.26 (-1.85%)
Closing price 03:59 PM Eastern
Extended Trading
$490.00 -0.73 (-0.15%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • The current stock price is around $479.98, which may present a buying opportunity for investors looking for growth in the life sciences sector.
  • The company reported strong quarterly earnings, exceeding analysts' expectations with earnings per share of $5.36, indicating robust financial health and operational efficiency.
  • Thermo Fisher Scientific Inc. has shown a revenue increase of 2.9% compared to the same quarter last year, suggesting a positive growth trajectory in its business operations.

Cons of Thermo Fisher Scientific

  • Insider selling has been notable, with executives recently selling shares, which may indicate a lack of confidence in the stock's short-term performance.
  • The stock has experienced a decrease in ownership percentage among corporate insiders, which could suggest a shift in sentiment regarding the company's future prospects.
  • Despite recent revenue growth, the company’s earnings per share have slightly declined compared to the same quarter last year, which may raise concerns about sustainability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$188.80 billion
P/E Ratio
28.38
Consensus Rating
Moderate Buy
Consensus Price Target
$593.00 (+20.8% Upside)
Volume
1.04 million shares
Average Volume
2.29 million shares
Today's Range
$489.18
$499.58
50-Day Range
$390.17
$500.24
52-Week Range
$385.46
$627.88
Dividend Yield
0.34%
Intuitive Surgical stock logo

11. Intuitive Surgical NASDAQ:ISRG

$468.44 -7.72 (-1.62%)
Closing price 04:00 PM Eastern
Extended Trading
$469.20 +0.75 (+0.16%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • The current stock price is around $550, which is significantly below its 12-month high of $616, indicating potential for growth.
  • Intuitive Surgical, Inc. reported a strong quarterly revenue of $2.44 billion, exceeding analysts' expectations, which reflects robust demand for its products.
  • The company has a high return on equity of 14.56%, suggesting effective management and profitability, which can be attractive to investors.

Cons of Intuitive Surgical

  • The stock has a high price-to-earnings ratio of 66.41, which may indicate that it is overvalued compared to its earnings, posing a risk for investors.
  • Insider selling has been notable, with executives selling thousands of shares, which could signal a lack of confidence in the stock's future performance.
  • The stock's beta of 1.59 suggests higher volatility compared to the market, which could lead to larger price swings and increased risk for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$170.69 billion
P/E Ratio
65.33
Consensus Rating
Moderate Buy
Consensus Price Target
$595.95 (+27.2% Upside)
Volume
1.66 million shares
Average Volume
1.98 million shares
Today's Range
$467.80
$477.87
50-Day Range
$469.81
$543.74
52-Week Range
$425.00
$616.00
Dividend Yield
N/A
Amgen stock logo

12. Amgen NASDAQ:AMGN

$288.47 -5.25 (-1.79%)
Closing price 04:00 PM Eastern
Extended Trading
$289.40 +0.93 (+0.32%)
As of 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • The current stock price is around $720, reflecting a stable investment opportunity in the biotechnology sector.
  • Amgen Inc. has a strong dividend yield of 3.2%, providing investors with a reliable income stream through dividends.
  • The company maintains a solid dividend payout ratio of approximately 77.84%, indicating a commitment to returning value to shareholders while still reinvesting in growth.

Cons of Amgen

  • Despite its strong product lineup, Amgen Inc. faces significant competition in the biotechnology sector, which could impact market share and profitability.
  • The high dividend payout ratio may limit the company's ability to reinvest in research and development, potentially hindering long-term growth.
  • Market volatility can affect stock performance, and recent fluctuations in the biotechnology sector may pose risks for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$158.13 billion
P/E Ratio
23.59
Consensus Rating
Hold
Consensus Price Target
$304.43 (+5.5% Upside)
Volume
1.73 million shares
Average Volume
2.11 million shares
Today's Range
$287.56
$294.60
50-Day Range
$272.44
$309.22
52-Week Range
$253.30
$339.17
Dividend Yield
3.24%
Boston Scientific stock logo

13. Boston Scientific NYSE:BSX

$105.18 -0.99 (-0.93%)
Closing price 03:59 PM Eastern
Extended Trading
$105.48 +0.29 (+0.28%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • The current stock price is around $104, which is near its 52-week high of $108.94, indicating strong market performance.
  • Boston Scientific Co. reported a significant year-over-year revenue increase of 22.8%, showcasing robust growth in its business operations.
  • The company has a solid return on equity of 19.21%, reflecting effective management and profitability in generating returns for shareholders.

Cons of Boston Scientific

  • The company has a relatively high P/E ratio of 63.09, which may suggest that the stock is overvalued compared to its earnings, potentially limiting future price appreciation.
  • Boston Scientific Co. has a quick ratio of 0.82, indicating that it may face challenges in meeting short-term liabilities without selling inventory, which could be a concern for liquidity.
  • Despite strong revenue growth, the net margin of 13.55% may indicate that the company faces pressure on profitability, which could affect future earnings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$157.32 billion
P/E Ratio
62.61
Consensus Rating
Buy
Consensus Price Target
$117.50 (+11.7% Upside)
Volume
4.51 million shares
Average Volume
6.32 million shares
Today's Range
$105.10
$106.20
50-Day Range
$101.35
$107.51
52-Week Range
$78.90
$108.94
Dividend Yield
N/A
Danaher stock logo

14. Danaher NYSE:DHR

$207.89 -3.91 (-1.85%)
Closing price 03:59 PM Eastern
Extended Trading
$209.42 +1.53 (+0.74%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • Danaher Co. has a strong market capitalization of approximately $151 billion, indicating a robust position in the market that can attract further investment and growth opportunities.
  • The current stock price is around $211, which is significantly lower than its 12-month high of nearly $280, suggesting potential for price appreciation as the market stabilizes.
  • Seventeen analysts have rated Danaher Co. with a Buy rating, reflecting strong confidence in the company's future performance and growth prospects.

Cons of Danaher

  • Several analysts have recently lowered their price targets for Danaher Co., with estimates now ranging from $225 to $240, which may indicate a lack of confidence in short-term growth.
  • The stock has a relatively high price-to-earnings (P/E) ratio of around 45, suggesting that it may be overvalued compared to its earnings, which could deter value-focused investors.
  • Despite positive earnings, the company has a PEG ratio of 2.85, indicating that its growth may not justify its current valuation, which could lead to price corrections.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$151.66 billion
P/E Ratio
44.23
Consensus Rating
Moderate Buy
Consensus Price Target
$247.61 (+19.1% Upside)
Volume
1.99 million shares
Average Volume
3.88 million shares
Today's Range
$207.29
$211.73
50-Day Range
$188.23
$212.24
52-Week Range
$171.00
$279.90
Dividend Yield
0.60%
Stryker stock logo

15. Stryker NYSE:SYK

$390.69 -3.53 (-0.89%)
Closing price 03:59 PM Eastern
Extended Trading
$391.27 +0.57 (+0.15%)
As of 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • The current stock price is around $445, reflecting a positive outlook from analysts who have recently upgraded their target prices.
  • Stryker Co. has a solid annualized dividend of $3.36, providing a dividend yield of 0.9%, which can be attractive for income-focused investors.
  • The company has a relatively low dividend payout ratio of 44.50%, indicating that it retains a significant portion of its earnings for reinvestment, which can support future growth.

Cons of Stryker

  • Despite the positive outlook, the stock has seen fluctuations, and recent insider selling by a director could raise concerns about the company's short-term prospects.
  • The dividend yield of 0.9% is relatively low compared to other investment opportunities, which may not attract all income-focused investors.
  • Analysts have mixed ratings, with some holding a "market perform" rating, indicating that not all experts are fully confident in the stock's potential for significant growth.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$150.71 billion
P/E Ratio
51.75
Consensus Rating
Moderate Buy
Consensus Price Target
$430.10 (+10.1% Upside)
Volume
970,955 shares
Average Volume
1.35 million shares
Today's Range
$389.35
$395.35
50-Day Range
$373.22
$403.34
52-Week Range
$329.16
$406.19
Dividend Yield
0.85%
Pfizer stock logo

16. Pfizer NYSE:PFE

$25.15 -0.73 (-2.82%)
Closing price 03:59 PM Eastern
Extended Trading
$25.17 +0.02 (+0.08%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • The current stock price is around $25.83, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • Pfizer Inc. recently reported earnings per share of $0.78, significantly exceeding the consensus estimate, indicating strong financial performance and potential for future growth.
  • The company has a solid revenue stream, with quarterly revenue of $14.65 billion, reflecting a year-over-year increase of 10.3%, showcasing its ability to grow even in competitive markets.

Cons of Pfizer

  • The stock has received a consensus rating of "Hold," indicating that analysts are not overwhelmingly bullish on its short-term prospects.
  • Pfizer Inc. has a relatively high dividend payout ratio of 91.49%, which may raise concerns about the sustainability of its dividend payments in the long run.
  • Despite recent earnings growth, the stock has a price-to-earnings (P/E) ratio of 13.74, which may suggest that it is fairly valued compared to its earnings potential.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$147.14 billion
P/E Ratio
13.38
Consensus Rating
Hold
Consensus Price Target
$28.12 (+11.8% Upside)
Volume
32.30 million shares
Average Volume
44.47 million shares
Today's Range
$25.11
$25.89
50-Day Range
$23.27
$25.83
52-Week Range
$20.92
$30.43
Dividend Yield
6.65%
Gilead Sciences stock logo

17. Gilead Sciences NASDAQ:GILD

$114.15 -0.62 (-0.54%)
Closing price 04:00 PM Eastern
Extended Trading
$114.42 +0.27 (+0.23%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More about Gilead Sciences

Pros of Gilead Sciences

  • The current stock price is around $115, reflecting a strong market position and investor interest.
  • Gilead Sciences, Inc. has a solid dividend yield of approximately 2.8%, providing a steady income stream for investors.
  • The company reported a positive earnings surprise, with earnings per share exceeding analyst expectations, indicating strong financial performance.

Cons of Gilead Sciences

  • The stock has experienced fluctuations, with a 12-month high of $121.83 and a low of $75.91, indicating potential volatility.
  • Despite recent revenue growth, the overall market sentiment can be influenced by broader economic conditions, which may affect stock performance.
  • Analysts have mixed ratings, with some holding a "neutral" stance, suggesting uncertainty about the stock's future trajectory.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$142.41 billion
P/E Ratio
22.74
Consensus Rating
Moderate Buy
Consensus Price Target
$115.39 (+1.1% Upside)
Volume
3.81 million shares
Average Volume
6.67 million shares
Today's Range
$113.81
$115.50
50-Day Range
$105.93
$120.47
52-Week Range
$76.42
$121.83
Dividend Yield
2.75%
Sanofi stock logo

18. Sanofi NASDAQ:SNY

$50.13 -1.22 (-2.38%)
Closing price 04:00 PM Eastern
Extended Trading
$49.96 -0.16 (-0.33%)
As of 06:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • Sanofi has received multiple upgrades from analysts, including a "strong-buy" rating, indicating strong confidence in the company's future performance.
  • The current stock price is around $50, which is considered attractive given the company's solid market capitalization of over $123 billion.
  • Sanofi reported a revenue of $11.34 billion in its latest quarter, significantly exceeding analyst expectations, showcasing strong operational performance.

Cons of Sanofi

  • Sanofi's earnings per share (EPS) of $0.90 fell short of analysts' consensus estimates, which could raise concerns about the company's growth trajectory.
  • The company's revenue has decreased by 7% year-over-year, indicating potential challenges in maintaining sales momentum.
  • Despite a strong market position, the stock has a relatively low price-to-earnings (P/E) ratio of around 12, which may suggest limited growth expectations from investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$126.09 billion
P/E Ratio
12.05
Consensus Rating
Buy
Consensus Price Target
$62.00 (+23.7% Upside)
Volume
1.66 million shares
Average Volume
2.79 million shares
Today's Range
$50.07
$51.14
50-Day Range
$45.64
$51.35
52-Week Range
$44.73
$60.12
Dividend Yield
3.11%
Medtronic stock logo

19. Medtronic NYSE:MDT

$92.02 -0.69 (-0.74%)
Closing price 03:59 PM Eastern
Extended Trading
$92.96 +0.94 (+1.02%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • The current stock price is around $92.62, which reflects a recent increase of 1.7%, indicating positive market sentiment.
  • Medtronic plc reported strong quarterly earnings, with earnings per share of $1.26, surpassing analysts' expectations, which suggests robust financial health.
  • The company has a solid revenue growth of 7.7% year-over-year, demonstrating its ability to expand and capture market share.

Cons of Medtronic

  • The stock has a relatively high price-to-earnings (P/E) ratio of around 25.52, which may suggest that it is overvalued compared to its earnings.
  • Medtronic plc's dividend payout ratio is currently at 78.24%, indicating that a significant portion of earnings is being distributed as dividends, which could limit reinvestment in growth opportunities.
  • Despite recent positive earnings, the stock has experienced volatility, with a twelve-month high of $96.25 and a low of $79.29, reflecting potential risks in price stability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$118.84 billion
P/E Ratio
25.35
Consensus Rating
Moderate Buy
Consensus Price Target
$101.15 (+9.9% Upside)
Volume
4.76 million shares
Average Volume
7.59 million shares
Today's Range
$91.92
$93.05
50-Day Range
$85.68
$93.13
52-Week Range
$79.29
$96.25
Dividend Yield
3.06%
Vertex Pharmaceuticals stock logo

20. Vertex Pharmaceuticals NASDAQ:VRTX

$388.94 -6.18 (-1.56%)
Closing price 04:00 PM Eastern
Extended Trading
$390.33 +1.39 (+0.36%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • The company recently reported earnings per share of $4.52, exceeding analysts' expectations, which indicates strong financial performance and potential for future growth.
  • Vertex Pharmaceuticals Incorporated has a robust return on equity of 23.91%, suggesting effective management and profitability in generating returns for shareholders.
  • With a net margin of 31.86%, the company demonstrates strong profitability, which can be attractive to investors looking for financially healthy companies.

Cons of Vertex Pharmaceuticals

  • Recent price target reductions by several analysts, including a decrease from $494 to $455, may indicate concerns about the stock's future performance.
  • The stock has experienced fluctuations, with a recent trading price down about 0.6%, which could signal volatility and risk for investors.
  • Despite strong earnings, the company posted a significant loss in the same quarter last year, which may raise questions about sustainability and consistency in performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$101.31 billion
P/E Ratio
27.80
Consensus Rating
Moderate Buy
Consensus Price Target
$497.10 (+27.8% Upside)
Volume
1.18 million shares
Average Volume
2.55 million shares
Today's Range
$387.60
$396.13
50-Day Range
$366.54
$479.53
52-Week Range
$362.50
$519.88
Dividend Yield
N/A
Bristol Myers Squibb stock logo

21. Bristol Myers Squibb NYSE:BMY

$47.15 -0.77 (-1.61%)
Closing price 03:59 PM Eastern
Extended Trading
$47.17 +0.02 (+0.04%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol Myers Squibb

Pros of Bristol Myers Squibb

  • The company recently reported earnings per share that exceeded expectations, indicating strong financial performance and potential for growth.
  • Bristol-Myers Squibb has a diverse portfolio of biopharmaceutical products, including recent advancements in treatments for various cancers and autoimmune diseases, which can drive future revenue.
  • The current stock price is around $47, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.

Cons of Bristol Myers Squibb

  • The company has a high debt-to-equity ratio, which may indicate financial risk and could affect its ability to invest in new projects or weather economic downturns.
  • Recent analyst downgrades and lowered price targets suggest that some market experts are cautious about the stock's short-term performance.
  • Despite a strong product lineup, the biopharmaceutical industry is highly competitive, and there is always the risk of new entrants or innovations that could impact market share.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$97.54 billion
P/E Ratio
19.01
Consensus Rating
Hold
Consensus Price Target
$56.38 (+19.6% Upside)
Volume
10.86 million shares
Average Volume
12.64 million shares
Today's Range
$46.94
$48.15
50-Day Range
$43.37
$48.99
52-Week Range
$42.96
$63.33
Dividend Yield
5.18%
HCA Healthcare stock logo

22. HCA Healthcare NYSE:HCA

$403.06 -1.91 (-0.47%)
Closing price 03:59 PM Eastern
Extended Trading
$400.00 -3.06 (-0.76%)
As of 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • The current stock price is around $404, reflecting a strong market position and investor interest.
  • HCA Healthcare, Inc. reported a significant earnings per share (EPS) of $6.84 for the latest quarter, exceeding analysts' expectations, which indicates robust financial performance.
  • Analysts have a consensus rating of "Moderate Buy" for HCA Healthcare, Inc., suggesting positive sentiment among market experts.

Cons of HCA Healthcare

  • The stock has a high debt-to-equity ratio of 69.07, which may indicate financial risk and reliance on debt financing.
  • Despite recent growth, the company has a negative return on equity, which could raise concerns about its profitability and efficiency in generating returns for shareholders.
  • Market volatility could impact HCA Healthcare, Inc.'s stock performance, as indicated by its beta of 1.39, suggesting higher sensitivity to market movements.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$94.76 billion
P/E Ratio
16.94
Consensus Rating
Moderate Buy
Consensus Price Target
$398.58 (-1.1% Downside)
Volume
805,488 shares
Average Volume
1.33 million shares
Today's Range
$401.36
$406.19
50-Day Range
$334.26
$410.19
52-Week Range
$289.98
$417.14
Dividend Yield
0.71%
CVS Health stock logo

23. CVS Health NYSE:CVS

$71.22 -0.08 (-0.11%)
Closing price 03:59 PM Eastern
Extended Trading
$71.39 +0.17 (+0.23%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • CVS Health Co. has demonstrated strong financial performance, with quarterly revenue increasing by over 8% year-over-year, indicating robust growth potential.
  • The company has set an earnings per share (EPS) guidance for FY 2025 between 6.300 and 6.400, suggesting confidence in future profitability.
  • Recent upgrades from multiple analysts, including UBS Group and Barclays, reflect positive market sentiment, with target prices reaching as high as $80.00.

Cons of CVS Health

  • Despite recent growth, some analysts have lowered their price targets, indicating potential concerns about the stock's short-term performance.
  • The dividend payout ratio of 74.30% may raise concerns about the sustainability of future dividends, especially if earnings do not meet expectations.
  • Insider ownership is relatively low at 1.22%, which may suggest a lack of confidence from those closest to the company.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$90.43 billion
P/E Ratio
19.89
Consensus Rating
Buy
Consensus Price Target
$76.67 (+7.6% Upside)
Volume
4.67 million shares
Average Volume
8.55 million shares
Today's Range
$70.40
$71.64
50-Day Range
$58.82
$71.40
52-Week Range
$43.56
$72.51
Dividend Yield
3.73%
McKesson stock logo

24. McKesson NYSE:MCK

$679.34 -10.11 (-1.47%)
Closing price 03:59 PM Eastern
Extended Trading
$671.50 -7.84 (-1.15%)
As of 07:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • The current stock price is around $720, reflecting a strong market position and investor confidence in the company's growth potential.
  • McKesson Co. recently increased its quarterly dividend to $0.82, indicating a commitment to returning value to shareholders and a healthy payout ratio of 11.32%.
  • The company reported a significant revenue increase of 23.4% compared to the same quarter last year, showcasing robust business growth.

Cons of McKesson

  • The company missed earnings expectations in its latest quarterly report, which may raise concerns about its short-term performance.
  • Insider selling has been notable, with significant shares sold by executives, which could indicate a lack of confidence in the stock's near-term prospects.
  • Despite revenue growth, McKesson Co. has a negative return on equity, suggesting inefficiencies in generating profit from shareholders' equity.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$85.76 billion
P/E Ratio
27.09
Consensus Rating
Moderate Buy
Consensus Price Target
$725.10 (+6.7% Upside)
Volume
709,715 shares
Average Volume
989,560 shares
Today's Range
$678.77
$693.31
50-Day Range
$658.78
$735.41
52-Week Range
$464.42
$737.89
Dividend Yield
0.41%
GSK stock logo

25. GSK NYSE:GSK

$39.68 -0.51 (-1.27%)
Closing price 03:59 PM Eastern
Extended Trading
$39.72 +0.04 (+0.10%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • GSK plc recently reported strong quarterly earnings, with an EPS of $1.23, exceeding analysts' expectations, indicating robust financial performance.
  • The company has a solid return on equity of 49.22%, suggesting effective management and profitability relative to shareholder equity.
  • GSK plc's current stock price is around $40, reflecting a stable market position and potential for growth.

Cons of GSK

  • The current ratio of 0.87 suggests that GSK plc may have liquidity issues, as it indicates that current liabilities exceed current assets.
  • With a debt-to-equity ratio of 1.07, GSK plc has a relatively high level of debt compared to equity, which could pose risks in times of financial stress.
  • The company recently cut its dividend, which may signal financial strain or a shift in strategy that could concern income-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$81.86 billion
P/E Ratio
18.37
Consensus Rating
Reduce
Consensus Price Target
$37.38 (-5.8% Downside)
Volume
1.88 million shares
Average Volume
3.85 million shares
Today's Range
$39.57
$40.24
50-Day Range
$36.21
$40.50
52-Week Range
$31.72
$44.67
Dividend Yield
4.19%
Cigna Group stock logo

26. Cigna Group NYSE:CI

$300.83 -3.52 (-1.16%)
Closing price 03:59 PM Eastern
Extended Trading
$298.50 -2.33 (-0.78%)
As of 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about Cigna Group

Pros of Cigna Group

  • The current stock price is approximately $304, which reflects a strong position in the market and potential for growth.
  • The Cigna Group has reported impressive earnings, with a recent EPS of $7.20, surpassing analyst expectations, indicating robust financial health.
  • The company has set a favorable FY 2025 guidance at 29.600 EPS, suggesting confidence in future profitability.

Cons of Cigna Group

  • Recent price target reductions by analysts, such as Barclays lowering it from $385 to $354, may signal concerns about future performance.
  • The stock has experienced fluctuations, with a 12-month high of $370.83 and a low of $256.89, indicating volatility that could deter risk-averse investors.
  • The company's debt-to-equity ratio of 0.65 suggests a moderate level of debt, which could impact financial stability in adverse conditions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$81.24 billion
P/E Ratio
16.42
Consensus Rating
Buy
Consensus Price Target
$374.82 (+24.6% Upside)
Volume
1.05 million shares
Average Volume
2.13 million shares
Today's Range
$298.78
$304.14
50-Day Range
$262.26
$334.71
52-Week Range
$256.89
$370.83
Dividend Yield
1.98%
Elevance Health stock logo

27. Elevance Health NYSE:ELV

$314.41 -2.14 (-0.68%)
Closing price 03:59 PM Eastern
Extended Trading
$313.98 -0.44 (-0.14%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$71.28 billion
P/E Ratio
13.38
Consensus Rating
Moderate Buy
Consensus Price Target
$413.81 (+31.6% Upside)
Volume
1.24 million shares
Average Volume
2.47 million shares
Today's Range
$312.63
$317.06
50-Day Range
$274.10
$395.76
52-Week Range
$273.71
$567.26
Dividend Yield
2.16%
Zoetis stock logo

28. Zoetis NYSE:ZTS

$155.10 -1.52 (-0.97%)
Closing price 03:59 PM Eastern
Extended Trading
$155.72 +0.62 (+0.40%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. More about Zoetis

Pros of Zoetis

  • The current stock price is around $156, which is relatively stable compared to its twelve-month high of $200.33, indicating potential for recovery and growth.
  • Zoetis Inc. reported a strong quarterly earnings performance, with earnings per share of $1.76, surpassing analysts' expectations, which reflects the company's robust financial health.
  • The company has a high return on equity of 56.90%, suggesting effective management and profitability, which can be attractive to investors looking for strong performance metrics.

Cons of Zoetis

  • Recent downgrades from multiple analysts, including a reduction in target prices, suggest a cautious outlook on the stock's short-term performance.
  • The company has seen insider selling, with an executive selling shares at an average price of $170, which may indicate a lack of confidence in the stock's near-term prospects.
  • Zoetis Inc. has a relatively high price-to-earnings (P/E) ratio of 26.91, which could suggest that the stock is overvalued compared to its earnings, making it less attractive for value investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$69.41 billion
P/E Ratio
26.70
Consensus Rating
Moderate Buy
Consensus Price Target
$202.43 (+30.5% Upside)
Volume
1.80 million shares
Average Volume
3.45 million shares
Today's Range
$154.89
$157.21
50-Day Range
$145.76
$164.36
52-Week Range
$139.70
$200.33
Dividend Yield
1.29%
Regeneron Pharmaceuticals stock logo

29. Regeneron Pharmaceuticals NASDAQ:REGN

$572.38 -17.10 (-2.90%)
Closing price 04:00 PM Eastern
Extended Trading
$574.19 +1.81 (+0.32%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • The current stock price is around $720, which reflects a strong performance in the biopharmaceutical sector.
  • Regeneron Pharmaceuticals, Inc. reported impressive earnings per share of $12.89 for the latest quarter, significantly exceeding analysts' expectations, indicating robust financial health.
  • The company has a solid market capitalization of approximately $62.85 billion, showcasing its stability and growth potential in the industry.

Cons of Regeneron Pharmaceuticals

  • The stock has a price-to-earnings (P/E) ratio of around 14.94, which may indicate that it is overvalued compared to its earnings, potentially deterring some investors.
  • Despite recent revenue growth, the company’s quarterly revenue increase of only 3.6% year-over-year may not meet the high growth expectations of some investors.
  • Analysts have mixed ratings on the stock, with some downgrading their recommendations, which could signal uncertainty about future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$62.48 billion
P/E Ratio
14.42
Consensus Rating
Moderate Buy
Consensus Price Target
$829.65 (+44.9% Upside)
Volume
880,542 shares
Average Volume
1.03 million shares
Today's Range
$572.25
$594.88
50-Day Range
$508.86
$598.16
52-Week Range
$476.49
$1,211.20
Dividend Yield
0.60%
Alnylam Pharmaceuticals stock logo

30. Alnylam Pharmaceuticals NASDAQ:ALNY

$443.64 -10.74 (-2.36%)
Closing price 04:00 PM Eastern
Extended Trading
$443.48 -0.15 (-0.03%)
As of 07:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More about Alnylam Pharmaceuticals

Pros of Alnylam Pharmaceuticals

  • The stock has received multiple "buy" ratings from analysts, indicating strong confidence in its future performance.
  • Recent earnings reports showed a significant revenue increase year-over-year, suggesting strong business growth.
  • The current stock price is around $454, which reflects a robust market presence and investor interest.

Cons of Alnylam Pharmaceuticals

  • The company has a negative price-to-earnings (P/E) ratio, which can indicate that it is not currently profitable.
  • High debt-to-equity ratio suggests that the company is heavily reliant on debt financing, which can be risky.
  • Insider selling activity has been noted, which may raise concerns about the executives' confidence in the company's future.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$59.56 billion
P/E Ratio
-179.61
Consensus Rating
Moderate Buy
Consensus Price Target
$405.33 (-8.6% Downside)
Volume
1.20 million shares
Average Volume
1.41 million shares
Today's Range
$442.38
$458.75
50-Day Range
$308.71
$467.55
52-Week Range
$205.87
$469.81
Dividend Yield
N/A
Becton, Dickinson and Company stock logo

31. Becton, Dickinson and Company NYSE:BDX

$194.70 -4.96 (-2.49%)
Closing price 03:59 PM Eastern
Extended Trading
$195.78 +1.08 (+0.56%)
As of 06:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • The company recently reported strong earnings, with an EPS of $3.68, surpassing analysts' expectations, indicating robust financial health.
  • Becton, Dickinson and Company has shown a significant revenue increase of 10.4% compared to the same quarter last year, reflecting growth in demand for its medical products.
  • The current stock price is around $171, which may present a buying opportunity for investors looking for value in the healthcare sector.

Cons of Becton, Dickinson and Company

  • The company's dividend payout ratio is currently 74.82%, which may indicate that a large portion of earnings is being distributed as dividends, potentially limiting reinvestment in growth opportunities.
  • Insider selling has been observed, with executives reducing their holdings, which could signal a lack of confidence in the company's future performance.
  • Despite recent revenue growth, the competitive landscape in the medical supply industry is intense, which may pressure margins and future profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$57.23 billion
P/E Ratio
35.02
Consensus Rating
Hold
Consensus Price Target
$211.44 (+8.6% Upside)
Volume
1.23 million shares
Average Volume
2.71 million shares
Today's Range
$194.03
$199.48
50-Day Range
$168.54
$199.50
52-Week Range
$163.33
$251.99
Dividend Yield
2.08%
Cencora stock logo

32. Cencora NYSE:COR

$288.20 -4.40 (-1.50%)
Closing price 03:59 PM Eastern
Extended Trading
$288.30 +0.10 (+0.04%)
As of 04:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • The current stock price is around $350, reflecting a strong market position and investor confidence.
  • Recent upgrades from multiple analysts, including a target price increase to $355, indicate positive market sentiment and potential for growth.
  • The company has a relatively low payout ratio of 22.63%, suggesting that it retains a significant portion of its earnings for reinvestment, which can drive future growth.

Cons of Cencora

  • Despite positive ratings, the stock's performance can be volatile, which may pose risks for investors looking for stability.
  • With 10.80% of the stock owned by insiders, there may be concerns about the level of control and influence they have over company decisions.
  • Market conditions can change rapidly, and any downturn in the pharmaceutical sector could negatively impact Cencora's stock performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$56.73 billion
P/E Ratio
29.65
Consensus Rating
Moderate Buy
Consensus Price Target
$311.25 (+8.0% Upside)
Volume
1.28 million shares
Average Volume
1.38 million shares
Today's Range
$287.79
$293.81
50-Day Range
$278.18
$303.36
52-Week Range
$218.65
$309.35
Dividend Yield
0.75%
IDEXX Laboratories stock logo

33. IDEXX Laboratories NASDAQ:IDXX

$641.35 -4.20 (-0.65%)
Closing price 04:00 PM Eastern
Extended Trading
$641.27 -0.08 (-0.01%)
As of 05:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • The current stock price is around $720, reflecting strong market interest and confidence in the company's growth potential.
  • Recent analyst upgrades have increased price targets significantly, with some analysts setting targets as high as $785, indicating a bullish outlook for the stock.
  • IDEXX Laboratories, Inc. has shown robust growth in its market segments, particularly in companion animal veterinary products, which are in high demand.

Cons of IDEXX Laboratories

  • Despite positive growth, the stock has experienced volatility, which may deter risk-averse investors looking for stable returns.
  • High valuations based on recent price targets could lead to a correction if the company fails to meet growth expectations.
  • With 87.84% of the stock owned by institutional investors, there may be less liquidity for retail investors, potentially impacting trading flexibility.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$51.65 billion
P/E Ratio
53.40
Consensus Rating
Moderate Buy
Consensus Price Target
$649.44 (+1.3% Upside)
Volume
395,639 shares
Average Volume
793,847 shares
Today's Range
$636.00
$644.13
50-Day Range
$514.61
$682.78
52-Week Range
$356.14
$688.12
Dividend Yield
N/A
Takeda Pharmaceutical stock logo

34. Takeda Pharmaceutical NYSE:TAK

$15.08 -0.44 (-2.84%)
Closing price 03:59 PM Eastern
Extended Trading
$14.94 -0.15 (-0.96%)
As of 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • The current stock price is around $14.77, which reflects a recent increase in trading volume, indicating heightened investor interest.
  • Takeda Pharmaceutical Company Limited has shown strong revenue performance, with quarterly revenues recently reported at approximately $7.34 billion, although slightly below analyst expectations.
  • The company has a solid market capitalization of about $46.98 billion, suggesting a stable position in the pharmaceutical industry.

Cons of Takeda Pharmaceutical

  • The company recently reported earnings per share (EPS) of $0.16, which fell short of the consensus estimate, raising concerns about its profitability.
  • Takeda Pharmaceutical Company Limited's net margin is relatively low at 3.20%, indicating that the company retains a smaller portion of revenue as profit compared to its peers.
  • Despite a strong market cap, the stock has experienced fluctuations, with a recent high of $15.53 and a low of $12.80 over the past year, suggesting volatility.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$49.38 billion
P/E Ratio
50.27
Consensus Rating
Hold
Consensus Price Target
N/A
Volume
2.81 million shares
Average Volume
5.20 million shares
Today's Range
$15.07
$15.32
50-Day Range
$13.60
$15.55
52-Week Range
$12.80
$15.56
Dividend Yield
3.60%
Edwards Lifesciences stock logo

35. Edwards Lifesciences NYSE:EW

$80.92 -0.91 (-1.11%)
Closing price 03:59 PM Eastern
Extended Trading
$80.88 -0.05 (-0.06%)
As of 05:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Market Capitalization
$48.04 billion
P/E Ratio
11.64
Consensus Rating
Moderate Buy
Consensus Price Target
$85.90 (+6.2% Upside)
Volume
4.39 million shares
Average Volume
4.20 million shares
Today's Range
$80.85
$82.23
50-Day Range
$73.31
$81.76
52-Week Range
$64.00
$83.00
Dividend Yield
N/A
Veeva Systems stock logo

36. Veeva Systems NYSE:VEEV

$285.54 -5.32 (-1.83%)
Closing price 03:59 PM Eastern
Extended Trading
$286.00 +0.46 (+0.16%)
As of 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. More about Veeva Systems

Pros of Veeva Systems

  • The current stock price is around $282, which reflects a strong market position and potential for growth in the cloud-based software sector for life sciences.
  • Veeva Systems Inc. reported a significant increase in revenue, with a 16.7% year-over-year growth, indicating strong demand for its products and services.
  • The company has a solid net margin of 27.34%, showcasing its ability to convert revenue into profit effectively.

Cons of Veeva Systems

  • The price-to-earnings ratio of 61.66 indicates that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • The PEG ratio of 2.24 suggests that the stock's price may not be justified by its earnings growth, indicating potential overvaluation.
  • With a beta of 0.95, the stock is relatively stable but may not provide the high returns that more volatile stocks could offer, which might be a concern for aggressive investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$47.53 billion
P/E Ratio
60.50
Consensus Rating
Moderate Buy
Consensus Price Target
$274.17 (-4.0% Downside)
Volume
1.27 million shares
Average Volume
1.07 million shares
Today's Range
$285.00
$292.42
50-Day Range
$275.24
$292.77
52-Week Range
$197.01
$296.72
Dividend Yield
N/A
Haleon stock logo

37. Haleon NYSE:HLN

$9.68 -0.14 (-1.43%)
Closing price 03:59 PM Eastern
Extended Trading
$9.68 +0.01 (+0.05%)
As of 07:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More about Haleon

Pros of Haleon

  • Haleon plc recently increased its semi-annual dividend to $0.0555, reflecting a significant boost from the previous amount, which indicates a commitment to returning value to shareholders.
  • The current stock price is around $12.33, which aligns with the consensus price target set by analysts, suggesting potential for growth.
  • Several research firms have recently upgraded Haleon plc's stock ratings, with BNP Paribas raising it to a "strong-buy" and setting a target price of $13.40, indicating strong market confidence.

Cons of Haleon

  • Despite recent upgrades, some analysts have downgraded Haleon plc's stock rating to "hold," indicating caution among certain market participants.
  • The high dividend yield of 190.0% may raise concerns about sustainability, as such a high yield can sometimes indicate underlying financial instability.
  • Market volatility and economic uncertainties could impact consumer spending on healthcare products, potentially affecting Haleon plc's sales and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$44.04 billion
P/E Ratio
24.82
Consensus Rating
Moderate Buy
Consensus Price Target
$12.33 (+27.3% Upside)
Volume
4.21 million shares
Average Volume
9.71 million shares
Today's Range
$9.66
$9.82
50-Day Range
$9.28
$10.52
52-Week Range
$8.86
$11.42
Dividend Yield
1.13%
ResMed stock logo

38. ResMed NYSE:RMD

$285.76 -7.97 (-2.71%)
Closing price 03:59 PM Eastern
Extended Trading
$285.84 +0.08 (+0.03%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. More about ResMed

Pros of ResMed

  • Recent analyst upgrades have increased the price targets for ResMed Inc., with some analysts setting targets as high as $300, indicating strong market confidence in the company's growth potential.
  • The current stock price is around $298, reflecting a positive trend and investor interest, which could lead to potential gains for shareholders.
  • ResMed Inc. has received multiple "strong-buy" and "outperform" ratings from analysts, suggesting that the stock is viewed favorably in the market.

Cons of ResMed

  • Insider selling has occurred recently, with a total of 27,638 shares sold, which may raise concerns about the confidence of those closest to the company.
  • Despite positive ratings, one analyst downgraded the stock from "buy" to "hold," indicating some caution in the market regarding its future performance.
  • The healthcare market can be highly competitive and subject to regulatory changes, which may impact ResMed Inc.'s operations and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$43.01 billion
P/E Ratio
30.05
Consensus Rating
Moderate Buy
Consensus Price Target
$274.83 (-3.8% Downside)
Volume
847,947 shares
Average Volume
1.12 million shares
Today's Range
$285.10
$293.58
50-Day Range
$250.14
$293.48
52-Week Range
$199.92
$293.81
Dividend Yield
0.82%
Alcon stock logo

39. Alcon NYSE:ALC

$80.82 -1.20 (-1.46%)
Closing price 03:59 PM Eastern
Extended Trading
$80.99 +0.17 (+0.21%)
As of 07:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alcon Inc researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. More about Alcon

Pros of Alcon

  • The current stock price is approximately $91.50, reflecting a strong market position and potential for growth.
  • Alcon Inc. has shown a positive fifty-two week performance, indicating a solid upward trend in its stock value.
  • Institutional ownership is relatively high, suggesting that large investors have confidence in the company's future prospects.

Cons of Alcon

  • Despite recent positive trends, the average daily volume has decreased, which could indicate reduced investor interest.
  • The month-to-month change in shares shorted has shown fluctuations, which may suggest uncertainty in the stock's stability.
  • While institutional ownership is high, it also means that the stock could be more susceptible to large sell-offs by these investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$40.46 billion
P/E Ratio
37.59
Consensus Rating
Moderate Buy
Consensus Price Target
$96.06 (+18.9% Upside)
Volume
2.14 million shares
Average Volume
2.37 million shares
Today's Range
$80.76
$82.77
50-Day Range
$79.16
$92.25
52-Week Range
$78.11
$101.10
Dividend Yield
N/A
argenex stock logo

40. argenex NASDAQ:ARGX

$677.32 +17.32 (+2.62%)
Closing price 04:00 PM Eastern
Extended Trading
$677.34 +0.02 (+0.00%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenex

Pros of argenex

  • The company recently reported earnings per share (EPS) of $3.74, significantly exceeding the consensus estimate, indicating strong financial performance.
  • argenx SE has a high net margin of approximately 41%, suggesting efficient management and profitability, which can be attractive to investors.
  • With a current stock price around $649, the shares have shown resilience and potential for growth, making it an appealing investment opportunity.

Cons of argenex

  • Despite recent positive earnings, the stock has experienced volatility, which may pose risks for investors looking for stable returns.
  • High valuations based on recent price targets could lead to potential overvaluation, making the stock less attractive if growth does not meet expectations.
  • The biotechnology sector is highly competitive and subject to regulatory challenges, which could impact argenx SE's ability to bring products to market successfully.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$40.39 billion
P/E Ratio
34.73
Consensus Rating
Buy
Consensus Price Target
$757.88 (+11.9% Upside)
Volume
546,099 shares
Average Volume
437,224 shares
Today's Range
$674.54
$702.24
50-Day Range
$537.92
$690.32
52-Week Range
$510.05
$702.24
Dividend Yield
N/A
Humana stock logo

41. Humana NYSE:HUM

$297.78 -1.73 (-0.58%)
Closing price 03:59 PM Eastern
Extended Trading
$297.36 -0.41 (-0.14%)
As of 06:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • The current stock price is around $290, reflecting a recent increase, which may indicate positive market sentiment towards the company.
  • Humana Inc. reported a revenue increase of 9.6% compared to the same quarter last year, showcasing strong growth potential.
  • Analysts have given Humana Inc. a consensus rating of "Hold," with several recent upgrades indicating confidence in the company's stability.

Cons of Humana

  • The company recently missed earnings per share estimates, which could raise concerns about its short-term profitability.
  • Several analysts have downgraded their target prices for Humana Inc., indicating a cautious outlook on its future performance.
  • With a net margin of only 1.28%, the company may face challenges in maintaining profitability amidst rising operational costs.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$36.02 billion
P/E Ratio
22.85
Consensus Rating
Hold
Consensus Price Target
$283.29 (-4.9% Downside)
Volume
880,132 shares
Average Volume
1.88 million shares
Today's Range
$295.00
$300.50
50-Day Range
$220.08
$300.01
52-Week Range
$206.87
$382.72
Dividend Yield
1.18%
Cardinal Health stock logo

42. Cardinal Health NYSE:CAH

$146.18 -1.92 (-1.30%)
Closing price 03:59 PM Eastern
Extended Trading
$146.02 -0.16 (-0.11%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • The company has a strong dividend yield of approximately 1.4%, which can provide a steady income stream for investors.
  • Recent analyst ratings indicate a consensus of "Moderate Buy," suggesting positive sentiment among investment professionals.
  • Cardinal Health, Inc. has a solid earnings forecast, with analysts predicting earnings per share of around 7.95 for the current year, indicating potential growth.

Cons of Cardinal Health

  • Despite a strong dividend, the company's payout ratio is 31.63%, which may limit future dividend increases if earnings do not grow as expected.
  • Some analysts have recently lowered their price targets for the stock, indicating potential concerns about future performance.
  • Market volatility and economic uncertainties could impact the healthcare sector, affecting Cardinal Health, Inc.'s performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$35.37 billion
P/E Ratio
22.66
Consensus Rating
Moderate Buy
Consensus Price Target
$163.20 (+11.6% Upside)
Volume
1.67 million shares
Average Volume
2.60 million shares
Today's Range
$145.96
$148.80
50-Day Range
$146.18
$167.92
52-Week Range
$106.54
$168.44
Dividend Yield
1.38%
Agilent Technologies stock logo

43. Agilent Technologies NYSE:A

$119.15 -2.48 (-2.04%)
Closing price 03:59 PM Eastern
Extended Trading
$117.68 -1.47 (-1.23%)
As of 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • Agilent Technologies, Inc. recently reported earnings per share (EPS) of $1.31, exceeding analysts' expectations, which indicates strong financial performance and potential for future growth.
  • The company has shown a year-over-year revenue increase of 6.0%, suggesting a positive trend in sales and market demand for its products.
  • Agilent Technologies, Inc. has a solid return on equity of 25.92%, reflecting effective management and profitability relative to shareholder equity.

Cons of Agilent Technologies

  • Despite recent growth, the stock has experienced fluctuations, with a 12-month high of $153.84, indicating potential volatility that could concern risk-averse investors.
  • Insider selling activity, such as the CEO's recent sale of shares, may raise questions about the company's future prospects and management's confidence in its performance.
  • While institutional ownership is high at 87.41%, this could lead to increased volatility if large investors decide to sell their positions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$34.55 billion
P/E Ratio
29.42
Consensus Rating
Moderate Buy
Consensus Price Target
$139.77 (+17.3% Upside)
Volume
1.48 million shares
Average Volume
1.25 million shares
Today's Range
$118.48
$121.69
50-Day Range
$112.12
$124.18
52-Week Range
$96.43
$153.84
Dividend Yield
0.82%
BeOne Medicines stock logo

44. BeOne Medicines NASDAQ:ONC

$308.63 -5.04 (-1.61%)
As of 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Market Capitalization
$34.38 billion
P/E Ratio
N/A
Consensus Rating
Buy
Consensus Price Target
$330.89 (+7.2% Upside)
Volume
163,103 shares
Average Volume
412,149 shares
Today's Range
$307.60
$320.00
50-Day Range
$240.99
$321.36
52-Week Range
$170.99
$330.63
Dividend Yield
N/A
GE HealthCare Technologies stock logo

45. GE HealthCare Technologies NASDAQ:GEHC

$74.59 -0.63 (-0.84%)
Closing price 04:00 PM Eastern
Extended Trading
$74.55 -0.04 (-0.05%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. More about GE HealthCare Technologies

Pros of GE HealthCare Technologies

  • The current stock price is around $73.87, which may be considered attractive for potential investors looking for entry points in a stable company.
  • GE HealthCare Technologies Inc. reported strong quarterly earnings, with earnings per share of $1.06, exceeding analysts' expectations, indicating robust financial performance.
  • The company has a solid market capitalization of approximately $33.73 billion, reflecting its significant presence in the healthcare technology sector.

Cons of GE HealthCare Technologies

  • The stock has experienced fluctuations, with a 12-month high of $94.80 and a low of $57.65, indicating potential volatility that could concern risk-averse investors.
  • The price-to-earnings (P/E) ratio is around 15.14, which, while not excessively high, may suggest that the stock is fairly valued compared to its earnings growth potential.
  • The company has a debt-to-equity ratio of 0.85, which indicates a moderate level of debt that could pose risks if market conditions change.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$34.34 billion
P/E Ratio
15.28
Consensus Rating
Moderate Buy
Consensus Price Target
$88.55 (+18.7% Upside)
Volume
1.99 million shares
Average Volume
4.09 million shares
Today's Range
$74.00
$75.11
50-Day Range
$69.85
$77.74
52-Week Range
$57.65
$94.80
Dividend Yield
0.19%
IQVIA stock logo

46. IQVIA NYSE:IQV

$188.08 -3.07 (-1.61%)
Closing price 03:59 PM Eastern
Extended Trading
$188.12 +0.04 (+0.02%)
As of 06:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More about IQVIA

Pros of IQVIA

  • The current stock price is around $185, which reflects a strong market position and potential for growth in the medical research sector.
  • IQVIA Holdings Inc. reported a quarterly earnings per share (EPS) of $2.81, surpassing analyst expectations, indicating robust financial performance.
  • The company has shown a year-over-year revenue increase of 5.3%, suggesting a positive growth trajectory and resilience in its business model.

Cons of IQVIA

  • The company has a relatively high debt-to-equity ratio of 2.45, which may indicate potential financial risk and reliance on debt financing.
  • Insider trading activity shows a decrease in positions, with notable sales by insiders, which could signal a lack of confidence in the company's short-term performance.
  • Despite recent revenue growth, the company's quick and current ratios are both at 0.84, suggesting potential liquidity issues that could affect its ability to meet short-term obligations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$32.50 billion
P/E Ratio
27.22
Consensus Rating
Moderate Buy
Consensus Price Target
$228.62 (+21.6% Upside)
Volume
1.05 million shares
Average Volume
1.42 million shares
Today's Range
$187.01
$190.83
50-Day Range
$154.10
$201.06
52-Week Range
$134.65
$252.88
Dividend Yield
N/A
DexCom stock logo

47. DexCom NASDAQ:DXCM

$75.96 -6.30 (-7.66%)
Closing price 04:00 PM Eastern
Extended Trading
$76.17 +0.21 (+0.28%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. More about DexCom

Pros of DexCom

  • The current stock price is around $82.81, which is near its 50-day simple moving average, indicating potential stability in the short term.
  • DexCom, Inc. reported a strong earnings performance recently, with earnings per share (EPS) of $0.48, surpassing analyst expectations, which reflects the company's robust financial health.
  • The company has shown impressive revenue growth, with a year-over-year increase of 15.2%, suggesting strong demand for its continuous glucose monitoring systems.

Cons of DexCom

  • The company has a relatively high P/E ratio of 57.13, which may suggest that the stock is overvalued compared to its earnings, potentially deterring value-focused investors.
  • With a beta of 1.43, DexCom, Inc. is more volatile than the market, which could lead to larger price swings and increased risk for investors.
  • Insider ownership is only 0.32%, which may indicate a lack of confidence from those closest to the company, potentially raising concerns for outside investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$32.26 billion
P/E Ratio
52.75
Consensus Rating
Moderate Buy
Consensus Price Target
$99.89 (+31.5% Upside)
Volume
6.53 million shares
Average Volume
4.04 million shares
Today's Range
$75.89
$82.20
50-Day Range
$75.46
$89.53
52-Week Range
$57.52
$93.25
Dividend Yield
N/A
Insmed stock logo

48. Insmed NASDAQ:INSM

$128.32 -3.56 (-2.70%)
Closing price 04:00 PM Eastern
Extended Trading
$128.00 -0.32 (-0.25%)
As of 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Market Capitalization
$27.88 billion
P/E Ratio
-22.47
Consensus Rating
Moderate Buy
Consensus Price Target
$132.57 (+3.3% Upside)
Volume
1.98 million shares
Average Volume
3.25 million shares
Today's Range
$128.02
$132.73
50-Day Range
$96.14
$132.60
52-Week Range
$60.40
$133.56
Dividend Yield
N/A
Koninklijke Philips stock logo

49. Koninklijke Philips NYSE:PHG

$27.60 -0.74 (-2.61%)
Closing price 03:59 PM Eastern
Extended Trading
$27.60 -0.01 (-0.02%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. More about Koninklijke Philips

Pros of Koninklijke Philips

  • The current stock price is around $27.27, reflecting a recent increase of 1.0%, which may indicate positive market sentiment.
  • Institutional investors hold a significant portion of the stock, with 13.67% owned by hedge funds, suggesting confidence in the company's future performance.
  • Recent upgrades in stock ratings, with a consensus rating of "Moderate Buy," indicate analysts' optimism about the company's growth potential.

Cons of Koninklijke Philips

  • Recent downgrades in stock ratings, including a shift from "buy" to "hold," may signal caution among analysts regarding the company's short-term prospects.
  • Quantbot Technologies LP reduced its holdings by 20.0%, indicating potential concerns about the company's performance or market conditions.
  • The price-to-earnings ratio of 143.66 suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$27.29 billion
P/E Ratio
145.26
Consensus Rating
Buy
Consensus Price Target
N/A
Volume
713,408 shares
Average Volume
1.16 million shares
Today's Range
$27.59
$28.20
50-Day Range
$22.08
$28.32
52-Week Range
$21.48
$32.91
Dividend Yield
2.90%
Mettler-Toledo International stock logo

50. Mettler-Toledo International NYSE:MTD

$1,289.88 -31.57 (-2.39%)
Closing price 03:59 PM Eastern
Extended Trading
$1,289.85 -0.03 (0.00%)
As of 05:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mettler-Toledo International Inc manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. More about Mettler-Toledo International

Pros of Mettler-Toledo International

  • The current stock price is around $1,220, which is significantly higher than its one-year low of approximately $946, indicating strong market performance.
  • The company reported a quarterly earnings per share (EPS) of $10.09, surpassing analyst expectations, which reflects robust financial health and operational efficiency.
  • With a net margin of 21.46%, Mettler-Toledo International Inc. demonstrates effective cost management and profitability, making it an attractive investment.

Cons of Mettler-Toledo International

  • The company has a high price-to-earnings (P/E) ratio of 33.52, which may indicate that the stock is overvalued compared to its earnings, potentially leading to a price correction.
  • A negative return on equity of 476.07% raises concerns about the company's ability to generate profit from shareholders' equity, which could deter risk-averse investors.
  • The stock's beta of 1.34 suggests higher volatility compared to the market, meaning it may experience larger price swings, which could be risky for investors seeking stability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$27.22 billion
P/E Ratio
32.66
Consensus Rating
Moderate Buy
Consensus Price Target
$1,311.11 (+1.6% Upside)
Volume
85,847 shares
Average Volume
164,695 shares
Today's Range
$1,284.25
$1,325.67
50-Day Range
$1,147.24
$1,324.30
52-Week Range
$946.69
$1,521.01
Dividend Yield
N/A